ArticleCancers2021
A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy.
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 38 citations in OpenAlex.
- The interplay of Ashwagandha with hormonal dynamics and gut microbiota in women with breast cancer: a tri-axial perspective.Journal of natural medicines · 2026Review
- Exploring the molecular mechanism of cancer radiosensitization: the impact of physical stimulation therapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Review
- Chloroquine Alone and Combined with Antifungal Drug Against Candida albicans Biofilms In Vitro and In Vivo via Autophagy Inhibition.Mycopathologia · 2025Article
- The therapeutic potential of pegylated arginase I treatment in glioblastoma.Scientific reports · 2025Article
- Oleanolic acid activates the JNK-Sp1-DJ-1 axis to promote mitophagy-mediated neuroprotection in dopaminergic neurons for Parkinson's disease treatment.Archives of pharmacal research · 2025Article
- Single-cell landscape of peripheral immune cells in MASLD/MASH.Hepatology communications · 2025Article
- A multi-omics approach combining causal inference andFrontiers in immunology · 2025Article
- Rifaximin on epigenetics and autophagy in animal model of hepatocellular carcinoma secondary to metabolic-dysfunction associated steatotic liver disease.World journal of hepatology · 2024Article
- Low-Carbohydrate and Low-Fat Diet with Metabolic-Dysfunction-Associated Fatty Liver Disease.Nutrients · 2023Observational
- Sequencing Systemic Therapy in Hepatocellular Carcinoma.Current treatment options in oncology · 2023Review
- Recurrent atypical teratoid/rhabdoid tumors (AT/RT) reveal discrete features of progression on histology, epigenetics, copy number profiling, and transcriptomics.Acta neuropathologica · 2023Article
- Surgery on Metastatic Foci is a Better Strategy for Stage IV Breast Cancer Patients with only Nonregional Lymph Node Metastasis.Advances in therapy · 2023Article
- The function, mechanisms, and clinical applications of metformin: potential drug, unlimited potentials.Archives of pharmacal research · 2023Review
- The function, mechanisms, and clinical applications of metformin: potential drug, unlimited potentials.Archives of pharmacal research · 2023Review
- Arginine attenuates chronic mountain sickness in rats via microRNA-144-5p.Mammalian genome : official journal of the International Mammalian Genome Society · 2023Article
- miR-378a-3p promotes renal cell carcinoma proliferation, migration, and invasion by targeting TOB2.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies.Biomedicines · 2023Review
- Clinicopathological Features of Hepatocellular Carcinoma with Metabolic Risk Factors.Journal of hepatocellular carcinoma · 2023Article
- Traditional Chinese medicines and natural products targeting immune cells in the treatment of metabolic-related fatty liver disease.Frontiers in pharmacology · 2023Review
- Obesity under the moonlight of c-MYC.Frontiers in cell and developmental biology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 7 institutions in 4 countries.
Feifei GuoDepartment of Immunology, Ophthalmology and ENT, School of Medicine, Complutense University of Madrid, 12 de Octubre (imas12) Health Research Institute, 28040 Madrid, Spain.
Olga Estévez-VázquezDepartment of Immunology, Ophthalmology and ENT, School of Medicine, Complutense University of Madrid, 12 de Octubre (imas12) Health Research Institute, 28040 Madrid, Spain.ORCID 0000-0002-7983-8521
Raquel Benedé-UbietoDepartment of Immunology, Ophthalmology and ENT, School of Medicine, Complutense University of Madrid, 12 de Octubre (imas12) Health Research Institute, 28040 Madrid, Spain.
Douglas Maya-MilesInstitute of Biomedicine of Seville (IBiS), SeLiver Group, Virgen del Rocío University Hospital/CSIC/University of Seville, 41013 Seville, Spain.
Kang ZhengDepartment of Immunology, Ophthalmology and ENT, School of Medicine, Complutense University of Madrid, 12 de Octubre (imas12) Health Research Institute, 28040 Madrid, Spain.
Rocío Gallego-DuránInstitute of Biomedicine of Seville (IBiS), SeLiver Group, Virgen del Rocío University Hospital/CSIC/University of Seville, 41013 Seville, Spain.
Ángela RojasInstitute of Biomedicine of Seville (IBiS), SeLiver Group, Virgen del Rocío University Hospital/CSIC/University of Seville, 41013 Seville, Spain.
Javier AmpueroInstitute of Biomedicine of Seville (IBiS), SeLiver Group, Virgen del Rocío University Hospital/CSIC/University of Seville, 41013 Seville, Spain.
Manuel Romero-GómezInstitute of Biomedicine of Seville (IBiS), SeLiver Group, Virgen del Rocío University Hospital/CSIC/University of Seville, 41013 Seville, Spain.ORCID 0000-0001-8494-8947
Kaye PhilipDepartment of Pathology, Nottingham University Hospitals NHS Trust, Queen's Medical Centre Campus, Nottingham NG7 2UH, UK.
Isioma U EgbuniweDepartment of Pathology, Nottingham University Hospitals NHS Trust, Queen's Medical Centre Campus, Nottingham NG7 2UH, UK.ORCID 0000-0003-3752-3422
Chaobo ChenDepartment of Immunology, Ophthalmology and ENT, School of Medicine, Complutense University of Madrid, 12 de Octubre (imas12) Health Research Institute, 28040 Madrid, Spain.
Jorge SimonCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 28220 Madrid, Spain.ORCID 0000-0003-0404-6244
Teresa C DelgadoLiver Disease Laboratory, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain.ORCID 0000-0001-9204-581X
María Luz Martínez-ChantarCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 28220 Madrid, Spain.ORCID 0000-0002-6446-9911
Jie SunDepartment of Anesthesiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
Johanna ReissingDepartment of Internal Medicine III, University Hospital RWTH Aachen, 52074 Aachen, Germany.
Tony BrunsDepartment of Internal Medicine III, University Hospital RWTH Aachen, 52074 Aachen, Germany.ORCID 0000-0002-5576-6914
Arantza Lamas-PazDepartment of Immunology, Ophthalmology and ENT, School of Medicine, Complutense University of Madrid, 12 de Octubre (imas12) Health Research Institute, 28040 Madrid, Spain.ORCID 0000-0001-5857-4320
Manuel Gómez Del MoralDepartment of Cell Biology, Complutense University School of Medicine, 28040 Madrid, Spain.ORCID 0000-0002-0642-8142
Marius Maximilian WoitokDepartment of Internal Medicine III, University Hospital RWTH Aachen, 52074 Aachen, Germany.
Javier VaqueroCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 28220 Madrid, Spain.
José R RegueiroDepartment of Immunology, Ophthalmology and ENT, School of Medicine, Complutense University of Madrid, 12 de Octubre (imas12) Health Research Institute, 28040 Madrid, Spain.ORCID 0000-0001-8442-7762
Christian LiedtkeDepartment of Internal Medicine III, University Hospital RWTH Aachen, 52074 Aachen, Germany.ORCID 0000-0003-4681-7887
Christian TrautweinDepartment of Internal Medicine III, University Hospital RWTH Aachen, 52074 Aachen, Germany.
Rafael BañaresDepartment of Immunology, Ophthalmology and ENT, School of Medicine, Complutense University of Madrid, 12 de Octubre (imas12) Health Research Institute, 28040 Madrid, Spain.
Francisco Javier CuberoDepartment of Immunology, Ophthalmology and ENT, School of Medicine, Complutense University of Madrid, 12 de Octubre (imas12) Health Research Institute, 28040 Madrid, Spain.ORCID 0000-0003-1499-650X
Yulia A NevzorovaDepartment of Immunology, Ophthalmology and ENT, School of Medicine, Complutense University of Madrid, 12 de Octubre (imas12) Health Research Institute, 28040 Madrid, Spain.ORCID 0000-0003-1390-8002
Universidad Complutense de Madrid · ESCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESRWTH Aachen University · DECIC bioGUNE · ESNottingham University Hospitals NHS Trust · GBHospital General Universitario Gregorio Marañón · ESZhongda Hospital Southeast University · CN
Funding
AMMF 2018/117COST Action CA17112 and UCM-25/2019EXOHEP-CM S2017/BMD-3727German Research Foundation SFB 1382-403224013/A02 and B07Instituto de Salud Carlos III PI16/01842, PI19/01404 & PI19/00589La Caixa Foundation Program HR17-00601MINECO Retos SAF2016-78711, SAF2017-87919-R, PID2020-117827RB-IOO, PID2020-117941RB-IOO, PID2020-117116RB-I00NanoLiver-CM Y2018/NMT-4949programa de Financiación de Universidad Complutense de Madrid - Banco Santander, CT63/19.Proyectos Estratégicos-Fondos Feder PE-0451-2018Ramón y Cajal Researchers RYC-2014-15242 and RYC-2015-17438
Abstract
backgroundMetabolic-associated fatty liver disease (MAFLD) has risen as one of the leading etiologies for hepatocellular carcinoma (HCC). Oncogenes have been suggested to be responsible for the high risk of MAFLD-related HCC. We analyzed the impact of the proto-oncogene c-MYC in the development of human and murine MAFLD and MAFLD-associated HCC.
methodsalb-myc
resultsMild obesity, spontaneous hyperlipidaemia, glucose intolerance and insulin resistance were characteristic of 36-week-old alb-myc
conclusionsA novel function of c-MYC in MAFLD progression was identified opening new avenues for preventative strategies.
Indexed as
c-mycmetabolic-associated fatty liver disease (MAFLD)metforminoncogenetumorigenesis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.